2,312
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma

, ORCID Icon, , , , & ORCID Icon show all
Pages 732-736 | Received 22 Jul 2019, Accepted 14 Oct 2019, Published online: 27 Nov 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Iuliana Vaxman & Morie Gertz. (2020) Non-transplant eligible multiple myeloma: deciphering optimal first line regimens. Leukemia & Lymphoma 61:3, pages 504-506.
Read now

Articles from other publishers (2)

Chih-Ning Cheng, Shang-Yi Huang, Pei-Wen Lien, Shih-Ting Huang & Fang-Ju Lin. (2021) Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan. PLOS ONE 16:5, pages e0252124.
Crossref
Claudia Bellofiore, Giuseppe Sapienza, Uros Markovic, Vittorio Del Fabro, Alessandra Romano, Fabio Stagno, Corrado Tamburino, Sarah Mangiafico, Francesco Di Raimondo & Concetta Conticello. (2021) Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment. Clinical Lymphoma Myeloma and Leukemia 21:5, pages e456-e459.
Crossref